Reporting of Adverse Drug Reactions by Community Pharmacists: A Qualitative Study in Quebec

Drug Information Journal

Volumn 45, Issue 5, 2011, Pages 627-639

  Rouleau, Benoît ^a   Lavoie, Louise ^b   Leblanc, Jacinthe ^c   Moretti, Simon ^b   Collin, Chantal ^b  

^a MCGILL UNIVERSITY   (Canada)

^b Community Pharmacy ^*  (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

Adverse drug reaction; Pharmacist; Pharmacovigilance; Reporting; Surveillance

Indexed keywords

AMLODIPINE BESYLATE; GENERIC DRUG; METHYLPHENIDATE; METOPROLOL TARTRATE; OMEPRAZOLE; PANTOLAC; PANTOPRAZOLE; SALBUTAMOL; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; AWARENESS; CANADA; CLINICAL EFFECTIVENESS; DRUG FORMULATION; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MALE; MEDICAL PRACTICE; MEDICAL RESEARCH; PHARMACIST; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; QUALITATIVE RESEARCH; UNSPECIFIED SIDE EFFECT;

EID: 84860785027     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151104500613     Document Type: Article

References (30)

1. McGettigan P,Feely J.Adverse drug reaction reporting: Opinions and attitudes of medical practitioners in Ireland.Pharmacoepidemiol Drug Saf. 1995;4:355-358.
2. Health Canada. Drugs and health products. Adverse reaction information. http://www.hc-sc.gc.ca/dhp-mps/medeff/advers-react-neg/index-eng.php#a1 (accessed September 7, 2010).
3. Med Effect Program. www.hc-sc.gc.ca/dhp-mps/medeff/about-sujet-eng.php (accessed August 26, 2010).
4. Edwards IR,Aronson JK.Adverse drug reactions: Definitions, diagnosis, and management.Lancet. 2000;356:1255-1259.
5. Canada Vigilance Adverse Reaction Reporting. http://www.hc-sc.ca/dhp-mps/medeff/vigilance-eng.php (accessed August 26, 2010).
6. Standards of practice for Canadian pharmacists.Pharm Connect. 2010;17 (4): 12-22.
7. National Association of Pharmacy Regulatory Authorities. National statistics. http://napra.ca/pages/Practice_Resources/National_Statistics.aspx?id=2103 (accessed January 14, 2011).
8. National Association of Pharmacy Regulatory Authorities. http://napra.ca/pages/practice_resources/national_statistics_aspx?id=2104/ (accessed July 6, 2011).
9. Lopez-Gonzalez E,Herdeiro MT,Figueiras A.Determinants of under-reporting of adverse drug reactions: A systematic review.Drug Saf. 2009;32 (1): 19-31.
10. Hazell L,Shakir SA.Under reporting of adverse drug reactions: A systematic review.Drug Saf. 2006;29 (5): 385-396.
11. Motola D,Vargiu A,Leone R, et al.Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.Drug Saf. 2008;31 (7): 609-616.
12. Health Canada. Adverse reaction reporting-survey with health professionals. May 2007. HC POR 06-93.
13. vanGrootheest K,Olsson S,Couper M, et al.Pharmacists' role in reporting adverse drug reactions in an international perspective.Pharmacoepidemiol Drug Saf. 2004;13:457-464.
14. Canada Vigilance Adverse Reaction Reporting Program. Completion of form instructions. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/report-declaration/ar-ei_form-eng.pdf (accessed August 26, 2010).
15. Burkiewicz JS,Zgarrick DP.Evidence based practice by pharmacists: Utilization and barriers.Ann Pharmacother. 2005;39:1214-1219.
16. Brown CM,Barner JC,Shepherd MD.Issues and barriers related to the provision of pharmaceutical care in community health centers and migrant health centers.J Am Pharm Assoc. 2003;43:75-77.
17. Nadaira N,Ouellet C,Rene-Henri N, et al.Factors influencing a community pharmacist's interventions in asthma care.Can Pharmacists J. 2009;142 (5): 240-246.
18. Amsler MR,Murray MD,Tierney WM, et al.Pharmaceutical care in chain pharmacies: Beliefs and attitudes of pharmacists and patients.J Am Pharm Assoc. 1997;37:535-542.
19. Borgherini G.The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.Clin Ther. 2003;25 (6): 1578-1592.
20. Makus KG,McCormick J.Identification of adverse reactions that can occur on substitutions of generic for branded lamotrigine in patients with epilepsy.Clin Ther. 2007;29 (2): 334-341.
21. Chenu F,Batten LA,Zernig G, et al.Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: A crossover study.J Clin Psychiatry. 2009;70:958-966.
22. Vial J,Cohen M,Sassiat P, et al.Pharmaceutical quality of docetaxel generics versus originator drug product: A comparative analysis.Curr Med Res Opin. 2008;24:2019-2033.
23. LeLorier J,Duh MS,Paradis PE, et al.Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.Neurology. 2008;70:2179-2186.
24. Endrenyi L,Tothfalusi L.Do regulatory bio-equivalence requirements adequately reflect the therapeutic equivalence of modified release drug products?.J Pharm Pharmaceut Sci. 2010;13 (1): 107-113.
25. Andermann F,Duh MS,Gosselin A, et al.Compulsory generic switching of antiepileptic drugs: High switchback rates to branded compounds compared with other drug classes.Epilepsia. 2007;48 (3): 464-469.
26. LeLorier J,Duh MS,Paradis PE, et al.Economic impact of generic substitution of lamotrigine: Projected costs in the US using findings in a Canadian setting.Curr Med Res Opin. 2008;24:1069-1081.
27. Nichols V,Theriault-Dube I,Touzin J, et al.Risk perception and reasons for noncompliance in pharmacovigilance: A qualitative study conducted in Canada.Drug Saf. 2009;32:579-590.
28. Health Canada. Underutilization of the adverse reaction reporting system. June 2007 (HC-POR-06-83).
29. Green CF,Mottram DR,Raval D, et al.Community pharmacists' attitude to adverse drug reaction reporting.Int J Pharm Pract. 1999;7:92-99.
30. Sweis D,Wong IC.A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain.Drug Saf. 2000;23:165-172.